Lucid Diagnostics Inc.

Lucid Diagnostics Inc. (LUCD) priced its initial public offering on Oct 15, 2021 at $14.00 per share, raising $70M, and listed on Nasdaq. At the IPO price its market capitalization was about $517.9M. Cantor was lead-left underwriter, joined by Canaccord Genuity, BTIG and Needham. Graubard Miller advised the company and Duane Morris advised the underwriters.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on patients with chronic acid reflux who risk developing esophageal precancer and cancer. Its EsoGuard DNA test, run on samples taken with the EsoCheck collection device, is intended as a screening tool.

Status

IPO

Ticker

LUCD

Exchange

Nasdaq

Priced

Oct 15, 2021

IPO price

$14.00

Raised

$70M

Market cap at IPO price

$517.9M

First filed

Sep 22, 2021

Underwriters

Cantor, Canaccord Genuity, BTIG and Needham

Company counsel

Graubard Miller

Underwriters' counsel

Duane Morris

Sector

Healthcare

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.